Myalepta - direct healthcare professional communication (DHPC)

Metreleptin

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8mg vial: inconsistency in the Spanish language package leaflet

Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the Portuguese-language package leaflet

Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Portuguese-language package leaflet

Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 3 mg vial: inconsistency in the Spanish language package leaflet (PL)

Direct healthcare professional communication (DHPC): Myalepta (metreleptin) 5.8 mg vial: inconsistency in the English-language package leaflet (PL)

Key facts

• Medicine name:
  Myalepta
• Active substance:
  Metreleptin
• Therapeutic area (MeSH):
  Lipodystrophy, Familial Partial
• Procedure number:
  EMEA/H/C/004218
• DHPC type:
  Quality defect
• Human ATC codes:
  A16AA
• Dissemination date:
  18/06/2020